COLITE ULCEROSA SEVERA: DOPO GLI STEROIDI E’ MEGLIO INFLIXIMAB + AZATIOPRINA O LA SOLA AZATIOPRINA? ATTENZIONE AL TRIAL “ACTIVE” ! DA “GUT”

DISORDINI FUNZIONALI, DISPEPSIA, GASTROENTEROLOGIA, IBD, IBS, IBS, MEDICINA INTERNA, NEWSLETTER, Senza categoria

Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial Aurelien Amiot et al.  Abstract Background It is unknown which maintenance therapy is the most effective option for patients admitted for an acute severe ulcerative colitis (ASUC) episode responding…

UN’OTTIMA REVIEW SULLA PRIMARY BILIARY CHOLANGITIS. ANDATE A VEDERE ANCHE IL RUOLO DELL’ACIDO OBETICOLICO, OGGI IN DISCUSSIONE. DA “THE LANCET” (FREE)

APP CONSIGLIATE, EPATOLOGIA, EPATOLOGIA ONCOLOGICA, GASTROENTEROLOGIA, NEWSLETTER, Senza categoria, UTILITA'

Primary biliary cholangitis Prof Atsushi Tanaka et al. Summary Primary biliary cholangitis is a chronic, autoimmune, cholestatic disease that mainly affects women aged 40–70 years. Recent epidemiological studies have shown an increasing incidence worldwide despite geographical heterogeneity and a decrease in the female-to-male ratio of those the disease affects. Similar to other autoimmune diseases, primary…

OSTRUZIONE BILIARE DISTALE DA NEOPLASIA: COLEDOCODUODENOSTOMIA VIA ECOENDO O ERCP ? L’ACCESSO PERCUTANEO DOVREBBE ESSERE ABBANDONATO. UNA OTTIMA NETWORK META-ANALISI ITALIANA. DA “DIGESTIVE & LIVER DISEASE “

DISORDINI FUNZIONALI, DISPEPSIA, ECOGRAFIA ED ECOENDOSCOPIA, ENDOSCOPIA, EPATOLOGIA ONCOLOGICA, GASTROENTEROLOGIA, IBS, IBS, LIBRI, NEWSLETTER, ONCOLOGIA, PANCREAS E VIE BILIARI, QUADERNI, Senza categoria, utilità newsletter

Primary drainage of distal malignant biliary obstruction: A comparative network meta-analysis Gaetano Lauri et al. Abstract Background The effectiveness of various primary upfront drainage techniques for distal malignant biliary obstructions (dMBO) is not well-established. Objective To compare the technical and clinical success rates and adverse event (AE) rates of various primary drainage techniques. Methods We…

IBD: LA ASSEGNAZIONE AL GRUPPO PLACEBO DANNEGGIA IL PAZIENTE ASSEGNATO AL PLACEBO NEI TRIAL ? UNO SPLENDIDO EDITORIALE SULLE META-ANALISI DI SETTORE. DA “THE LANCET” (FREE)

CHIRURGIA, GASTROENTEROLOGIA, IBD, NEWSLETTER, Senza categoria

Do placebos harm patients in IBD trials? In 1955, Truelove and Witts published the first placebo-controlled, randomised clinical trial in inflammatory bowel disease (IBD), which showed the superiority of cortisone for the treatment of acute ulcerative colitis. In the acute phase of the trial there were more deaths in the placebo group than the active…

L’ILLUSIONE DI COMPRENDERE MEGLIO CON L’INTELLIGENZA ARTIFICIALE. UN GRANDE MONITO DA “NATURE”. RIFLETTETE, GENTE, RIFLETTETE!

METODOLOGIA, NEWSLETTER, REAL WORLD EVIDENCE, Senza categoria

Artificial intelligence and illusions of understanding in scientific research Lisa Messeri & M. J. Crockett Scientists are enthusiastically imagining ways in which artifcial intelligence (AI) tools might improve research. Why are AI tools so attractive and what are the risks of implementing them across the research pipeline? Here we develop a taxonomy of scientists’ visions for…

ATTENZIONE ! PRIMARY BILIARY CHOLANGITIS: ARRIVA SELADELPAR IN SECONDA LINEA (a peroxisome proliferator–activated receptor delta agonist). UN TRIAL FASE 3 DA “THE NEW ENGLAND JOURNAL OF MEDICINE”

EPATOLOGIA, EPATOLOGIA ONCOLOGICA, GASTROENTEROLOGIA, NEWSLETTER, Senza categoria

A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis Gideon M Hirschfield et al. Abstract Background: Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a peroxisome proliferator-activated receptor delta agonist, has potential benefits. Methods: In this phase 3, 12-month, double-blind, placebo-controlled trial, we randomly assigned (in a 2:1 ratio) patients who had had…